Evidence map›Paper›PMID 21674551›Full record

ReviewMedicinal research reviews2013

5-HT radioligands for human brain imaging with PET and SPECT.

Louise M Paterson, Birgitte R Kornum, David J Nutt, Victor W Pike, Gitte M Knudsen

Open access · bronzeAbstract readReview
In one paragraph

Review in Medicinal research reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2014
    Trial
  5. Synthesis andRSC medicinal chemistry · 2024
    Article
  6. Article
  7. Annals of nuclear medicine · 2024
    Article
  8. The utility of PET imaging in depression.Frontiers in psychiatry · 2024
    Review
  9. Article
  10. Radiotracers for the Central Serotoninergic System.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  11. Opposite alterations of 5-HTTranslational psychiatry · 2021
    Article
  12. Review
  13. Review
  14. Advances in simultaneous PET/MR for imaging neuroreceptor function.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Review
  15. Serotonin release measured in the human brain: a PET study with [Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  16. Characterization of the serotonin 2A receptor selective PET tracer (R)-[European journal of nuclear medicine and molecular imaging · 2020
    Article
  17. Review
  18. Kinetic analysis of [BMC veterinary research · 2019
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Louise M PatersonNeuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, Burlington Danes Building, Du Cane Road, London, United Kingdom.
Birgitte R Kornum
David J Nutt
Victor W Pike
Gitte M Knudsen
Imperial College London · GBUniversity of Copenhagen · DKNational Institute of Mental Health · US

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Intramural NIH HHS ZIA MH002793Medical Research Council G1002226
6 · The paper itself

Abstract

The serotonergic system plays a key modulatory role in the brain and is the target for many drug treatments for brain disorders either through reuptake blockade or via interactions at the 14 subtypes of 5-HT receptors. This review provides the history and current status of radioligands used for positron emission tomography (PET) and single photon emission computerized tomography (SPECT) imaging of human brain serotonin (5-HT) receptors, the 5-HT transporter (SERT), and 5-HT synthesis rate. Currently available radioligands for in vivo brain imaging of the 5-HT system in humans include antagonists for the 5-HT(1A), 5-HT(1B), 5-HT(2A), and 5-HT(4) receptors, and for SERT. Here we describe the evolution of these radioligands, along with the attempts made to develop radioligands for additional serotonergic targets. We describe the properties needed for a radioligand to become successful and the main caveats. The success of a PET or SPECT radioligand can ultimately be assessed by its frequency of use, its utility in humans, and the number of research sites using it relative to its invention date, and so these aspects are also covered. In conclusion, the development of PET and SPECT radioligands to image serotonergic targets is of high interest, and successful evaluation in humans is leading to invaluable insight into normal and abnormal brain function, emphasizing the need for continued development of both SPECT and PET radioligands for human brain imaging.

Indexed as

SerotoninBrainHumansPositron-Emission TomographyRadiopharmaceuticalsReceptors, SerotoninSerotonin AntagonistsSerotonin Plasma Membrane Transport ProteinsTomography, Emission-Computed, Single-PhotonRadiopharmaceuticalsReceptors, SerotoninSerotoninSerotonin AntagonistsSerotonin Plasma Membrane Transport ProteinsSLC6A4 protein, human

Identifiers

PMID21674551
PMCPMC4188513
OpenAlexW1526312511

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.